- Home
- ALLK vs OPRX Comparison
ALLK vs OPRX Comparison
Compare ALLK & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- OPRX
- Stock Information
- Founded
- ALLK 2012
- OPRX 2006
- Country
- ALLK United States
- OPRX United States
- Employees
- ALLK N/A
- OPRX N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- OPRX Business Services
- Sector
- ALLK Health Care
- OPRX Consumer Discretionary
- Exchange
- ALLK Nasdaq
- OPRX Nasdaq
- Market Cap
- ALLK 101.0M
- OPRX 111.2M
- IPO Year
- ALLK 2018
- OPRX N/A
- Fundamental
- Price
- ALLK $0.86
- OPRX $4.81
- Analyst Decision
- ALLK Hold
- OPRX Buy
- Analyst Count
- ALLK 4
- OPRX 8
- Target Price
- ALLK $1.67
- OPRX $9.06
- AVG Volume (30 Days)
- ALLK 827.7K
- OPRX 255.6K
- Earning Date
- ALLK 03-13-2025
- OPRX 11-13-2024
- Dividend Yield
- ALLK N/A
- OPRX N/A
- EPS Growth
- ALLK N/A
- OPRX N/A
- EPS
- ALLK N/A
- OPRX N/A
- Revenue
- ALLK N/A
- OPRX $88,179,506.00
- Revenue This Year
- ALLK N/A
- OPRX $28.03
- Revenue Next Year
- ALLK N/A
- OPRX $11.43
- P/E Ratio
- ALLK N/A
- OPRX N/A
- Revenue Growth
- ALLK N/A
- OPRX 40.40
- 52 Week Low
- ALLK $0.54
- OPRX $3.78
- 52 Week High
- ALLK $1.69
- OPRX $16.65
- Technical
- Relative Strength Index (RSI)
- ALLK 35.16
- OPRX 43.65
- Support Level
- ALLK $0.81
- OPRX $4.66
- Resistance Level
- ALLK $1.00
- OPRX $5.14
- Average True Range (ATR)
- ALLK 0.13
- OPRX 0.42
- MACD
- ALLK -0.03
- OPRX -0.05
- Stochastic Oscillator
- ALLK 8.43
- OPRX 10.51
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.